Sinovac Biotech Ltd.
No.39 Shangdi Xi Rd
Haidian District
Beijing
100085
China
Tel: 86-10-82890088
Fax: 86-10-62966910
Website: http://www.sinovac.com/
Email: sinovac@sinovac.com
422 articles about Sinovac Biotech Ltd.
-
SEC Concludes Investigation of Sinovac
8/20/2018
The SEC determined that it will not recommend or pursue an enforcement action against Sinovac at this time.
-
Declaration of Board of Directors of Sinovac Biotech Co., Ltd.
8/1/2018
To safeguard the legitimate interests of Sinovac Biotech Ltd. and its shareholders, the Current Board hereby makes the following statements:
-
An Open Letter from Sinobioway Consortium to All Shareholders of Sinovac Biotech Ltd.
7/26/2018
On February 6, 2018, Sinovac Biotech Ltd. held its 2017 Annual Meeting of Shareholders in Beijing, China.
-
Sinovac Raises $86.73 Million Through Private Placement Transaction
7/3/2018
Vivo Capital and Advantech Capital Each Hold an Approximately 8.3% Stake in Sinovac After the Private Placement Transaction
-
Sinovac Biotech Relaunches Company Website
6/11/2018
Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), today announced that the company has relaunched its website, at www.sinovacbio.com.
-
Sinovac Forced to Temporarily Suspend Flu Vaccine Production Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing
5/1/2018
Sinovac Biotech Ltd. announced it has been forced to temporarily suspend its flu vaccine production and destroy the flu vaccines it is currently producing.
-
Sinovac Temporarily Blocks Access to Its Websites
4/30/2018
Sinovac Biotech Ltd. announced that Aihua Pan, the Chairman of the Board of the Company's controlled Chinese subsidiary, Sinovac Biotech Co., Ltd. inappropriately and without authorization seized control of the Company's websites, www.sinovac.com and www.sinovac.com.cn.
-
Sinovac Forced to Plan to Destroy Bacterial Seeds intended for Pneumo Vaccine Production and Postpone Site Inspection
4/30/2018
Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company") today announced it has been forced to destroy the bacterial seeds intended for use in the production of its 23-valent pneumococcal polysaccharide vaccine, or PPV, and to suspend all preparations for and ultimately postpone the China Food and Drug Administration (CFDA) inspection of the manufacturing site necessary for 23-valent PPV production approval
-
Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing
4/27/2018
Sinovac Biotech Ltd. announced that it will delay the filing of its annual report on Form 20-F for the year 2017.
-
Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction
4/27/2018
Sinovac Biotech Ltd. announced that on April 26, 2018, it entered into Amendment No. 2 to the Amalgamation Agreement (the "Amendment") to further amend the Amalgamation Agreement.
-
Sinovac Announces Preliminary Results of Phase III Trial on sIPV
4/19/2018
Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical study on Sabin inactivated polio vaccine ("sIPV") developed by Sinovac Biotech Co., Ltd. ("Sinovac Beijing") on the unblinding conference held on April 19, 2018.
-
Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd.
4/18/2018
Sinovac Biotech Ltd. today issued the following statement to set the record straight following a series of false statements and damaging actions by Shandong Sinobioway Biomedicine Co., Ltd. intended to mislead and publicly harm the interest of Sinovac and our shareholders.
-
Sinovac Sets the Record Straight Regarding False Statements by Unauthorized Third Parties
3/15/2018
Leading provider of biopharmaceutical products in China, today responded to public statements made by other parties falsely claiming to control the Company, including a press release falsely purporting to come from Sinovac itself.
-
Sinovac Announces Enhancement of Corporate Governance and Management of China Operating Entity
3/6/2018
Sinovac Biotech Ltd. announced actions taken to enhance the corporate governance and management of Sinovac Biotech Co., Ltd., the main operating subsidiary of Sinovac.
-
Sinovac Provides Update on Going Private Transaction
2/7/2018
Attached as an exhibit to the Going-Private Statement is a preliminary proxy statement.
-
Sinovac Holds 2017 Annual General Meeting of Shareholders
2/7/2018
Sinovac Biotech announced today that it held its 2017 Annual General Meeting of Shareholders on Tuesday, February 6, 2018 in Beijing, PRC.
-
Sinovac Schedules 2017 Annual Meeting of Shareholders
12/29/2017
Sinovac announced today that it will hold its 2017 Annual Meeting of Shareholders on Tuesday, February 6, 2018 at 9:00 a.m.
-
Sinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine From WHO
12/27/2017
Sinovac Biotech announced today that it has received a positive decision from the WHO on the acceptability, in principle, of its Healive, a hepatitis A vaccine product, for purchase by United Nations agencies.
-
Sinovac Reports Unaudited First Half of 2017 Financial Results
12/1/2017
Sinovac Biotech announced today that it reported its unaudited financial results for the six months ended June 30, 2017.
-
Sinovac Biotech Cures Nasdaq Filing Deficiency
12/1/2017
In the letter, Nasdaq indicated that the Company is in compliance with all applicable listing standards.